Barcelona

• A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas Halted
  2022-502137-26-00 1 2024-05-03 B-cell Non-Hodgkins Lymphoma (B-NHL)
• A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1) Halted
  2023-503823-24-01 3 2024-04-15 Systemic Sclerosis
• Comparative clinical trial of efficacy and satisfaction of 2% gel lidocaine versus tetracaine/oxybuprocaine anesthetic eye drops in patients … Halted
  2023-505131-13-01 6 2024-01-11 Glaucoma
• A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine … Halted
  2023-505829-14-00 5 2023-12-22 First recurrence glioblastoma
• Phase 2 Study of CAL02 plus Standard of Care in Severe Community-Acquired Bacterial Pneumonia (SCABP) Halted
  2022-502049-91-00 4 2023-09-26 SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
• Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta … Halted
  2024-511708-18-00 4 2022-12-06 Locally advanced or metastatic KRAS G12C-mutated non-small cell lung c
• A phase 1/2 study of subcutaneous blinatumomab administration in adults and adolescents with R/R and MRD+ B-ALL Halted
  2023-506136-32-00 9 2020-10-12 Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (
• A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety … Suspended
  2024-511244-12-01 5 Amyotrophic Lateral Sclerosis
• A phase 1 Clinical Trial to Evaluate Safety and Immunogenecity of HIV SOSIP v8.2 763 Vaccine in healthy individuals Ended
  2025-520529-19-00 1 2026-05-20 Human Immunodeficiency Virus (HIV)
• Phase 1 study to investigate the pharmacokinetic profile and safety of 3 testosterone gel formulations in postmenopausal female participants … Ended
  2025-522726-12-00 3 2025-12-16 No medical conditions.
• GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended
  2025-521107-42-00 4 2025-11-25 Alzheimer's Disease
• A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations Ended
  2025-521480-12-00 1 2025-10-22 Advanced solid tumors, Breast Cancer
• A First-in-human study to learn how safe the study drug BAY2965501 is, find the best dose (single drug & combination), how it affects the bo … Ended
  2023-507905-33-00 1 2025-09-30 Advanced solid tumors
• A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients with Overt Hepatic Encep … Ended
  2025-521029-34-00 4 2025-09-18 Patients with overt hepatic encephalopathy (OHE) and acute decompensat
• A phase III, international, multiCenter, randomized, paraLlel-group, Endoscopist-blinded non-inferiority study of the efficAcy, safety and p … Ended
  2025-521451-23-00 5 2025-09-03 Subjects scheduled for elective colonoscopy performed according to ESG
• A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended
  2023-507705-34-00 5 2025-08-29 Moderate to Severe Active Ulcerative Colitis
• Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection Ended
  2024-519856-94-00 4 2025-08-18 Cystic fibrosis
• A trial to learn how safe saruparib is and how well it works in people with advanced ovarian cancer Ended
  2024-519044-32-00 9 2025-08-06 Advanced/Recurrent Ovarian cancer
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis Ended
  2024-513440-29-00 10 2025-06-25 Sickle cell disease vaso-occlusive crisis
• A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors Ended
  2024-514745-10-00 1 2025-06-23 Melanoma (or) malignant melanoma Non-small cell lung cancer Head and n
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patien … Ended
  2024-517322-26-00 1 2025-06-06 EGFR-Mutant Non-Small Cell Lung Cancer
• A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers. Ended
  2023-508759-38-00 1 2025-06-04 Relapsed/Refractory B-cell Malignancies
• Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP Ended
  2024-515386-34-00 4 2025-05-29 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• A study to learn about the study medicine called PF-08046032 in people with advanced cancers. Ended
  2024-517756-35-00 3 2025-05-28 Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell

Showing 2,545–2,568 of 3,391 trials